OCT 21·SEC EDGARLow
Giroux Richard sold $557K of MGTX
Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $9.95 ($0.56M total) on 2026-10-20 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$MGTX
MeiraGTx Holdings plc
Price · $MGTXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $MGTX in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $851K 2 txs
Naylor Stuart1× · $294K
10b5-1 share of filings100%
Top stories · $MGTXMore →
SEP 24·investing.com
Goldman Sachs initiates MeiraGTx stock coverage with neutral rating
Goldman Sachs initiated coverage on MeiraGTx (MGTX) with a Neutral rating and $16.00 price target, up from $11.75. The company focuses on gene therapies for retinal diseases, xerostomia, and Parkinson’s. Analysts expect profitability this year. MeiraGTx secured a $400M investment deal with Oberland Capital, including capped royalties and equity. Other analysts maintain Buy ratings with higher price targets.
SEP 23·SEC EDGAR 8-K
MeiraGTx Holdings plc (MGTX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors LONDON and NEW YORK, September 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, tod
MGTX sentiment & insider activity
Recent MGTX coverage spans corporate actions, insider activity and earnings.
In the last 30 days, MGTX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($851K). The most active reporter was Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving MGTX
The insider sale may signal reduced confidence from a top executive, potentially pressuring the stock.
Analyst coverage and a sizable non‑dilutive capital raise could lift sentiment and support near‑term price appreciation.
Board appointment adds experienced biotech investor to governance, modest positive sentiment.
The filing discloses an insider sale by the CEO, which can modestly affect near-term sentiment but does not change fundamentals by itself.
New FDA designation and a completed product acquisition materially improve near-term regulatory and commercialization optionality, while funding and timelines reduce financing and execution uncertainty.
AlphAI scores every news story that mentions MGTX with an AI model for sentiment and relevance, and aggregates insider trades from MeiraGTx Holdings plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $MGTX
Score
Giroux Richard sold $557K of MGTX
Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $9.95 ($0.56M total) on 2026-10-20 under a Rule 10b5-1 trading plan.
2 min readGoldman Sachs initiates MeiraGTx stock coverage with neutral rating
Goldman Sachs initiated coverage on MeiraGTx (MGTX) with a Neutral rating and $16.00 price target, up from $11.75. The company focuses on gene therapies for retinal diseases, xerostomia, and Parkinson’s. Analysts expect profitability this year. MeiraGTx secured a $400M investment deal with Oberland Capital, including capped royalties and equity. Other analysts maintain Buy ratings with higher price targets.
3 min readMeiraGTx Holdings plc (MGTX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors LONDON and NEW YORK, September 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, tod
1 min readForbes Alexandria sold $859K of MGTX
Forbes Alexandria (PRESIDENT & CEO) sold 62,000 shares of MeiraGTx Holdings plc (MGTX) at $13.86 ($0.86M total) on 2026-08-18 under a Rule 10b5-1 trading plan.
2 min readMeiraGTx Reports Second Quarter 2026 Financial and Operational Results
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe
5 min readGiroux Richard sold $701K of MGTX
Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $12.51 ($0.70M total) on 2026-07-21 under a Rule 10b5-1 trading plan.
1 min read
MeiraGTx secures $400m from Oberland Capital
MeiraGTx said it will receive up to $375m in non-dilutive capital from Oberland Capital via capped royalties, plus up to $25m in equity. An initial $135m was funded, including $125m in low single-digit royalties and a $10m equity stake. Additional payments total $150m tied to Phase II completion and regulatory approvals for AAV2-hAQP1 and bota-vec.
4 min read
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
MeiraGTx Holdings (Nasdaq: MGTX) said it agreed with Oberland Capital for up to $400m to fund development/commercialization of AAV2-hAQP1 (RIX), bota-vec (XLRP) and AAV-AIPL1. Oberland will provide up to $375m in non-dilutive capped royalty funding and up to $25m equity, with additional tranches tied to 2027–2028 data/approvals.
4 min readMeiraGTx Holdings plc (MGTX): Entry into a Material Definitive Agreement
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 mgtx-20260630xex10d1.htm EX-10.1 Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Execution Version ROYALTY NOTE PUR
6 min readMeiraGTx Holdings plc (MGTX): Submission of Matters to a Vote of Security Holders
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MeiraGTx Holdings plc_June 11, 2026 0001735438 false 0001735438 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of
2 min read